Evidence map›Paper›PMID 35989897›Full record

ArticleCanadian liver journal2021

Single Topic Conference on Autoimmune Liver Disease from the Canadian Association for the Study of the Liver.

Aldo J Montano-Loza, Jessica R Allegretti, Angela Cheung, Maryam Ebadi, David Jones, Nanda Kerkar, Cynthia Levy, Sumera Rizvi, John M Vierling, Fernando Alvarez and 14 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian liver journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. A milestone for theCanadian liver journal · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 17 institutions in 3 countries.

Aldo J Montano-LozaDivision of Gastroenterology and Liver Unit, University of Alberta, Edmonton, Alberta, Canada.
Jessica R AllegrettiDivision of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Angela CheungMayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
Maryam EbadiDivision of Gastroenterology and Liver Unit, University of Alberta, Edmonton, Alberta, Canada.
David JonesFaculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.
Nanda KerkarDivision of Gastroenterology, Hepatology and Nutrition, Golisano Children's Hospital at Strong, University of Rochester Medical Center, New York, USA.
Cynthia LevySchiff Center for Liver Diseases, University of Miami, Miami, Florida, USA.
Sumera RizviMayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
John M VierlingBaylor College of Medicine, Houston, Texas, USA.
Fernando AlvarezDepartment of Pediatrics, Hôpital Sainte-Justine, University of Montreal, Montreal, Quebec, Canada.
Wayne BaiDivision of Gastroenterology and Liver Unit, University of Alberta, Edmonton, Alberta, Canada.
Susan GilmourStollery Children's Hospital, University of Alberta, Edmonton, Alberta, Canada.
Aliya GulamhuseinAjmera Family Transplant Centre, Toronto General Research Institute, Departments of Laboratory Medicine and Pathobiology and Immunology, University of Toronto, Toronto, Ontario, Canada.
Orlee GuttmanDivision of Gastroenterology, Hepatology and Nutrition, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.
Bettina E HansenAjmera Family Transplant Centre, Toronto General Research Institute, Departments of Laboratory Medicine and Pathobiology and Immunology, University of Toronto, Toronto, Ontario, Canada.
Sonya MacParlandAjmera Family Transplant Centre, Toronto General Research Institute, Departments of Laboratory Medicine and Pathobiology and Immunology, University of Toronto, Toronto, Ontario, Canada.
Andrew MasonDivision of Gastroenterology and Liver Unit, University of Alberta, Edmonton, Alberta, Canada.
Fernanda OnofrioAjmera Family Transplant Centre, Toronto General Research Institute, Departments of Laboratory Medicine and Pathobiology and Immunology, University of Toronto, Toronto, Ontario, Canada.
Pere SantamariaDepartment of Microbiology, Immunology & Infectious Diseases, University of Calgary, Calgary, Alberta, Canada.
Ashley StueckDepartment of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.
Mark SwainCalgary Liver Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada.
Catherine VincentDepartment of Medicine, University of Montreal, Montreal, Quebec, Canada.
Amanda RicciutoDivision of Gastroenterology, Hepatology and Nutrition, Hospital for Sick Children, Toronto, Ontario, Canada.
Gideon HirschfieldToronto Centre for Liver Disease, University Health Network & Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
University of Toronto · CAMayo Clinic · USUniversity of Alberta · CAUniversity of Alberta Hospital · CAUniversity of Calgary · CABaylor College of Medicine · USBrigham and Women's Hospital · USBritish Columbia Children's Hospital · CACentre Hospitalier Universitaire Sainte-Justine · CADalhousie University · CAGolisano Children's Hospital · USHospital for Sick Children · CANewcastle University · GBStollery Children's Hospital · CAToronto General Hospital · CAUniversité de Montréal · CAUniversity of Miami · US

Funding

Medical Research Council MR/L001489/1
6 · The paper itself

Abstract

Autoimmune liver disease (AILD) spans a spectrum of chronic disorders affecting the liver parenchyma and biliary system. Three main categories of AILD are autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). This review condenses the presentation and discussions of the Single Topic Conference (STC) on AILD that was held in Ottawa, Ontario, in November 2019. We cover generalities regarding disease presentation and clinical diagnosis; mechanistic themes; treatment paradigms; clinical trials, including approaches and challenges to new therapies; and looking beyond traditional disease boundaries. Although these diseases are considered autoimmune, the etiology and role of environmental triggers are poorly understood. AILDs are progressive and chronic conditions that affect survival and quality of life. Advances have been made in PBC treatment because second-line treatments are now available (obeticholic acid, bezafibrate); however, a significant proportion still present suboptimal response. AIH treatment has remained unchanged for several decades, and data suggest that fewer than 50% of patients achieve a complete response and as many as 80% develop treatment-related side effects. B-cell depletion therapy to treat AIH is in an early stage of development and has shown promising results. An effective treatment for PSC is urgently needed. Liver transplant remains the best option for patients who develop decompensated cirrhosis or hepatocellular carcinoma within specific criteria, but recurrent AILD might occur. Continued efforts are warranted to develop networks for AILD aimed at assessing geo-epidemiological, clinical, and biochemical differences to capture the new treatment era in Canada.

Indexed as

autoimmune hepatitiscirrhosisoverlap syndromeprimary biliary cirrhosisprimary sclerosing cholangitis.

Identifiers

PMID35989897
PMCPMC9235119
OpenAlexW3168102107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.